DIDO1
DIDO1 is involved in apoptosis and cellular differentiation. Alterations have been studied in hematologic malignancies and may have emerging relevance in targeted therapy research.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where DIDO1 is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Colorectal Cancer (CRC) Solid Tumor · Colorectal |
|
Approvals defined at the solid tumor level where DIDO1 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report DIDO1 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports DIDO1 as part of its biomarker panel.